Authors: V. O. Kholin, K. M. Poletaeva, A. A. Tikhonenko, N. Yu. D. F. Chebotareva NAMS of Ukraine, Kyiv
The available scientific and clinical data on the effect of the SARS-CoV-2 virus on the central nervous system (CNS) raise many questions for scientists and clinicians, given its undeniable negative impact on the CNS both in the acute and post-reconvalescence period. Whatever terms are applied to the existing neurological disorders that may appear in people who have had a coronavirus disease (long-term COVID or post-COVID syndrome), these disorders cause concern for doctors, patients and have a significant impact on overall health, ability to work, and even on the quality of life of people.
In the context of the treatment and rehabilitation of patients with post-COVID syndrome and existing cognitive impairments in the Department of Age Physiology and Pathology of the Nervous System, State Institution “Institute of Gerontology named after A.I. D. F. Chebotareva of the National Academy of Medical Sciences of Ukraine” conducts an open clinical observation on the use of Ripronate (meldonium), Metacartin (L-carnitine), Carmetadine (trimetazidine) manufactured by World Medicine as a metabolic therapy for post-covid syndrome and an additional component in the treatment of cognitive impairment and asthenic.